Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Genitourinary 3Plasma cell 1Head & Neck 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 136Lenalidomide 79daratumumab 77Bortezomib 66pomalidomide 48Cyclophosphamide 48carfilzomib 43Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 22iberdomide 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19Melphalan 18talquetamab 17fludarabine phosphate 14elotuzumab 12selinexor 11X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
fluciclovine F-18 × Plasma cell × 90 days × Clear all
NCT06103838 2026-05-29

18F-Fluciclovine PET/CT in Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡